EICHOR
● Recruiting
REBECCA Real-world Early BrEast CanCer mAnagement
Condition: Breast Cancer · Sponsor: AstraZeneca
About this study
This is a French observational, national, multicenter prospective cohort study of patients with HER2-negative eBC treated with olaparib at their physician's discretion.
This description comes directly from the study's public registry record.
Talk to the study team
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
Locations (58)
| Research Site | Clermont-Ferrand, Auvergne-Rh ne-Alpes, France | Recruiting |
| Research Site | Gleizé, Auvergne-Rh ne-Alpes, France | Recruiting |
| Research Site | Grenoble, Auvergne-Rh ne-Alpes, France | Not Yet Recruiting |
| Research Site | Lyon, Auvergne-Rh ne-Alpes, France | Recruiting |
| Research Site | Metz-Tessy, Auvergne-Rh ne-Alpes, France | Recruiting |
| Research Site | Saint-Etienne, Auvergne-Rh ne-Alpes, France | Not Yet Recruiting |
| Research Site | Saint-Priest-en-Jarez, Auvergne-Rh ne-Alpes, France | Not Yet Recruiting |
| Research Site | Thonon-les-Bains, Auvergne-Rh ne-Alpes, France | Recruiting |
| Research Site | Valence, Auvergne-Rh ne-Alpes, France | Recruiting |
| Research Site | Valence, Auvergne-Rh ne-Alpes, France | Not Yet Recruiting |
| Research Site | Dijon, Bourgogne-Franche-Comt, France | Not Yet Recruiting |
| Research Site | Plérin, Brittany Region, France | Recruiting |
+ 46 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.